Grifols, S.A.
GRFSHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeGrifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and. The $5.27B market capitalization puts GRFS squarely in mid-cap range for its industry. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Market Cap
$5.27B
Beta
1.17
P/E (TTM)
10.90
P/E (Fwd)
5.36
EPS (TTM)
$0.71
EPS (Fwd)
$1.44
ROE
6.1%
ROA
4.2%
Cash
$702.0M
Total Debt
$9.67B
Free CF
$887.5M
52W Change
-7.2%
Annual Financials
Cash vs Debt
The company holds $702.0M in cash, though total debt stands at $9.67B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $887.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 6.1%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $6.06B (2022) to $7.52B (2025), reflecting a 24% increase over the period.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GRFS.